PROMETHEUS PROTOCOL
THEEND OF AGING STARTS WITH YOUR CELLS
SCROLL TO EXPAND
Our MissionPioneering the shift from reactive medicine to proactive healthspan optimization
Celljevity is pioneering the shift from reactive medicine to proactive healthspan optimization, using the best of stem cell science, AI, and elite clinical care.
A world where aging is not inevitable decline, but a treatable condition. Where health is personalized, predictive, and preventive.
Learn MoreCertified Excellence


The Prometheus ProtocolIn Action
Our revolutionary cellular rejuvenation process combines cutting-edge science with proven clinical results, delivering unprecedented age reversal at the cellular level.
Cellular Rejuvenation
Transform aged cells into youthful, vibrant cells through our proprietary Prometheus Protocol.
Telomere Extension
Achieve unprecedented +32% telomere extension, reversing cellular aging markers to new-born stage.
Proprietary Protocol
From initial consultation to cell delivery—our complete rejuvenation process takes approximately 12 weeks.
Multi-System Applications
Comprehensive cellular rejuvenation across skin, joints, cardiovascular, cognitive, immune, and metabolic health.
The Journey to Renewal
The Rejuvenation Process
From collection to results in six precise steps.
Tissue Collection
A small 1cm² skin biopsy is collected from behind the ear under local anesthesia
Cell Isolation
Fibroblasts are isolated and expanded in our GMP-certified laboratories
Rejuvenation Protocol
Proprietary 15-day protocol reverses cellular aging markers
Quality Validation
Single-cell RNA sequencing confirms successful rejuvenation before release
Therapeutic Delivery
20 billion rejuvenated cells delivered via targeted injection or IV infusion
Results & Monitoring
Extended telomeres and rejuvenated cellular markers confirmed through comprehensive testing
Our complete rejuvenation process takes approximately 12 weeks from initial consultation to cell delivery
Learn MoreThe Science Behind Prometheus
Why Epigenetic Reprogramming Works
Aging isn't about worn-out parts—it's about cells that have forgotten how to function. Prometheus Therapy doesn't replace your cells; it updates their operating system.
Based on Dr. Sun's 190+ publications (20,000+ citations) in Nature, Science, and Cell.
Senolytics
Senescent cells accumulate with age, poisoning healthy neighbors. Prometheus Cells identify and eliminate these cellular troublemakers while regenerating tissue.
Epigenetics
DNA methylation patterns control cellular age. Prometheus Therapy resets these patterns—like restoring a vintage car to factory condition without replacing the engine.
Metabolism
Mitochondria lose efficiency with age. Epigenetic reprogramming restores youthful energy production, verified through 32% telomere extension.
Immunology
Aging skews immune responses toward inflammation. Prometheus Cells secrete IL-10 and modulate regulatory T-cells, restoring immune homeostasis.
Global Elite Partner Network
Temples of Transformation
These are not medical offices. They are sanctuaries where science meets soul, where cutting-edge regenerative medicine is delivered in environments designed for total rejuvenation.

Antibes, France
Clinique DelMar
Where luxury meets regenerative medicine on the stunning Côte d'Azur. Our flagship facility combines Mediterranean serenity with cutting-edge cellular therapies, offering the complete Prometheus protocol in an environment designed for healing.
Coming 2026
Global Expansion
Florida, Switzerland, and UAE. Bringing the Celljevity experience to major cities worldwide, each clinic collecting proprietary data to continuously improve our protocols.
The Prometheus Technology
Considerations (Educational Only)
Prometheus protocol is for adults aiming to reverse biological aging, prevent age-related decline, and enhance vitality via cellular rejuvenation.
The following information is educational only. Consult your physician to determine if these treatments may be appropriate for your individual circumstances.
Who Can Benefit from Prometheus Protocol
Our personalized screening process ensures Prometheus therapy is safe and optimal for each candidate, with eligibility criteria designed to maximize therapeutic outcomes.
Criteria & Screening:
Minimum Age: 16
Optimal Age: 40+ with early–moderate age-related decline
Comprehensive Screening: Medical evaluation by care teams
Protocol Considerations:
Adults 40+ with decline in vitality, recovery speed, resilience.
Joint/mobility issues (mild–moderate osteoarthritis, degeneration)
Preventive longevity care
Autoimmune/chronic inflammatory conditions
Biological age reversal (telomere extension)
High-performance individuals (executives, athletes, entrepreneurs)
The research protocol is personalized + eligibility screened.
Learn About EligibilityRequest information about eligibility requirements and treatment considerations. Our team can provide educational resources to help you discuss these options with your healthcare provider.
Latest from Our Blog
Research stories, clinical insights, and platform updates
Explore the latest regenerative discoveries, clinic-ready playbooks, and product launch updates from the Celljevity platform.

Diederik van der Reijt - Celljevity: Pioneering the Future of Cellular Rejuvenation
CEO Diederik van der Reijt discusses Celljevity's vision for revolutionizing healthcare through cellular therapy and the company's ambitious growth plans.

Inclusive Healthcare: Celljevity's Mission to Broaden Access to Advanced Therapies
Celljevity's innovative approach to making advanced cellular therapies accessible to broader populations through strategic partnerships and global expansion.

Breakthrough in Cellular Reprogramming: How Celljevity's Prometheus Therapy Reverses Biological Aging
Revolutionary cellular reprogramming technology shows promising results in reversing biological aging markers and restoring cellular function.
Our Team
World-Class Leadership
Led by experienced executives and guided by distinguished advisors
Leadership Team
Diederik van der Reijt
Chief Executive Officer
Serial biotech entrepreneur and investor founded Celljevity (cellular rejuvenation) and co-founded NKore Biotherapeutics (immunotherapies). Leveraging his background in trading and venture capital, he aims to scale science-backed innovations and democratize access to breakthrough cellular therapies.
Dr. Henk Viëtor
Chief Medical Officer
Co-founded and led more than 20 life sciences companies, including Drug Discovery Factory, Skyline Diagnostics, Julius Clinical, DC4U, MyLife Technologies, and Oncodrone. Physician, scientist, and serial biotech entrepreneur with expertise in clinical immunology, transfusion medicine, and genetics.
David Maman
Chief Operational Officer
Serial entrepreneur, involved in creating startups and projects since the 90s. Worked in Paris, London, New York, Dubai, Abu Dhabi, Luxembourg, Tel Aviv etc. Since 2000s, held executive positions in several international groups.
Dr. Digvijay Gahtory
Chief Business Officer
Has over 8 years of experience in strategy consulting and entrepreneurship. Has raised more than €100 million in financing for life science companies. Founder and CEO of Bimini Biotech.
Karen Brink
Chief Growth Officer
Focuses on growth strategies and thought leadership. Skilled and experienced investor who has founded several healthcare companies. Holds a Blockchain Strategy degree from Oxford.
Rhys Tombling
Finance Director
Has 10 years of experience in the private sector, specializing in financial control & operations for start-ups and scale-ups in FMCG and SaaS. Holds an ACA-ICAEW accountancy qualification and a BA in Accountancy and Finance from Newcastle University.
Dan Fobes
Chief Technology Officer
Formerly Senior Director Business Intelligence at Humana, Director of Technology Architecture and Digital at Novartis and Pfizer.
Daniel Erasmus
Chief Artificial Intelligence Architect
Furqan Athar
President MENA Operations
Medical & Scientific Board
Dr. Yi Eve Sun
Chief Science Officer
Professor, UCLA Department of Molecular & Medical Pharmacology. Pioneer in neural stem cell biology and leading expert in cellular reprogramming. Academic excellence with breakthrough discoveries in JAK-STAT pathways and successful translation from bench to bedside.
Dr. Henry Delmar
Founder, Clinic Del Mar
Member of the European Board of Plastic Surgeons (EBOPRAS), specializes in Plastic, Reconstructive, and Aesthetic Surgery. President of the French Society of Aesthetic Plastic Surgery (SOFCEP) and member of IPRAS and ESPRAS.
Dr. Adeel Khan
Board-Certified Physician
Board-certified physician and Co-founder of Minicircle, specializing in stem cell therapy and gene therapy applications. University of Ottawa medical graduate with clinical expertise in regenerative treatments. Through Eterna Health, operates international clinics focusing on cutting-edge longevity interventions.
Dr. Christopher Juel-Jensen
Chief Integration Officer
Surgeon, investment banker, and leader in longevity and regenerative medicine. Combines finance and medicine, previously working at J.P. Morgan, Goldman Sachs, Deutsche Bank, and Swiss Bank Corp., now developing healthcare and wellness platforms worldwide.
Dr. Pierre Maldiney
Cardiologist & Anti-Aging Physician
Cardiologist, morphologist, and anti-aging physician with training in nutritional and functional medicine with Professor Vincent Castronovo. President of AEM2F, the European Association of Mitronutrition and Functional Medicine.
Dr. Lin Quan
Clinical Director, UCLA
Clinical Director for preclinical research, focusing on Auto-rFib therapy research with expertise in cell culture and animal experiments. Leads preclinical investigations for neurodegenerative disease applications.
Doris Rathgeber
Medical Director, Body & Soul
Founder and Medical Director of Body & Soul in Shanghai. With over 20 years' experience in Traditional Chinese and Western Medicine, specializes in women's health, fertility, and pediatrics, delivering care in four languages.
Dr. Murat Bozkurt
Medical Advisor
Advisory Board
Paul Spiegel
Strategic Advisor
International business development executive with extensive experience in Asia-Pacific markets and cross-border partnerships. Specializes in strategic planning and market expansion for biotechnology companies, with deep expertise in regulatory affairs and commercial strategy.
Neil Bush
Senior Advisor
Global business leader with 40+ years experience specializing in cross-border investments in Asia and the Middle East. Founder of the George H. W. Bush Foundation for U.S.-China Relations. Chairs Points of Light and the Bush School Advisory Board.
Anne Popkin
Strategic Advisor
Senior executive and strategic advisor with extensive experience in finance, biotechnology, and investor advocacy. Recognized for leadership roles at major asset management firms and commitment to advancing women's representation in finance. Active philanthropist supporting education, science, and ocean preservation.
Stephen Bradley
Non-Executive Director
Former British Consul-General to Hong Kong, graduated from Oxford in 1980 and studied at Fudan University. Leverages extensive diplomatic experience across Asia to advise on cross-border consultancy and strategic development. Serves on the boards of Cenovus Energy Inc., CK Asset Holdings, and Power Assets Holdings.
Jamie Grooms
Executive Board Member
Highly recognized biotechnology entrepreneur and innovator. Founded and led companies including Synogen, AxoGen, RTI Biologics, and NeXtGen Biologics. Decades of experience as CEO and board member in regenerative medicine, medical devices, and biotech venture capital.
David Bizer
Investment Advisor
Co-founder and Managing Partner of GCW Global Customised Wealth, specializing in private equity and family office investments. Previously held senior positions at Jasper Ridge Partners, Nomura, and Lehman Brothers. Has served as an economic advisor to two U.S. Presidents. Ph.D. in Economics from Stanford University.
Rachid Bouzouba
Co-Founder, MCM Partners
Co-Founder and Chairman of MCM Partners, a Hong Kong-based merchant bank and corporate advisory firm. Accomplished finance executive with extensive leadership in global equities and derivatives, previously serving as Head of Global Equities at Nomura and Head of European Equities at Lehman Brothers.
Shirin Azad
Strategic Advisor
Questions & Answers
Frequently Asked Questions
Everything you need to know about Prometheus therapy
Can't find what you're looking for? Contact our specialist team
Treatment Process
Clinical & Scientific
Practical Information
Still have questions? Contact our specialist team
Contact UsMedical Disclaimer: Celljevity's Prometheus technology is investigational and not FDA-approved. Research protocol options vary by jurisdiction. Individual results may vary. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent disease. Consult your healthcare provider.
